231 related articles for article (PubMed ID: 36354038)
1. Intermediate-dose versus low-dose low-molecular-weight heparin in pregnant and post-partum women with a history of venous thromboembolism (Highlow study): an open-label, multicentre, randomised, controlled trial.
Bistervels IM; Buchmüller A; Wiegers HMG; Ní Áinle F; Tardy B; Donnelly J; Verhamme P; Jacobsen AF; Hansen AT; Rodger MA; DeSancho MT; Shmakov RG; van Es N; Prins MH; Chauleur C; Middeldorp S; ;
Lancet; 2022 Nov; 400(10365):1777-1787. PubMed ID: 36354038
[TBL] [Abstract][Full Text] [Related]
2. Low-molecular-weight heparin to prevent recurrent venous thromboembolism in pregnancy: Rationale and design of the Highlow study, a randomised trial of two doses.
Bleker SM; Buchmüller A; Chauleur C; Ní Áinle F; Donnelly J; Verhamme P; Jacobsen AF; Ganzevoort W; Prins M; Beyer-Westendorf J; DeSancho M; Konstantinides S; Pabinger I; Rodger M; Decousus H; Middeldorp S
Thromb Res; 2016 Aug; 144():62-8. PubMed ID: 27289488
[TBL] [Abstract][Full Text] [Related]
3. Apixaban versus no anticoagulation for the prevention of venous thromboembolism in children with newly diagnosed acute lymphoblastic leukaemia or lymphoma (PREVAPIX-ALL): a phase 3, open-label, randomised, controlled trial.
O'Brien SH; Rodriguez V; Lew G; Newburger JW; Schultz CL; Orgel E; Derr K; Ranalli MA; Esbenshade AJ; Hochberg J; Kang HJ; Dinikina Y; Mills D; Donovan M; Dyme JL; Favatella NA; Mitchell LG;
Lancet Haematol; 2024 Jan; 11(1):e27-e37. PubMed ID: 37980924
[TBL] [Abstract][Full Text] [Related]
4. Antepartum dalteparin versus no antepartum dalteparin for the prevention of pregnancy complications in pregnant women with thrombophilia (TIPPS): a multinational open-label randomised trial.
Rodger MA; Hague WM; Kingdom J; Kahn SR; Karovitch A; Sermer M; Clement AM; Coat S; Chan WS; Said J; Rey E; Robinson S; Khurana R; Demers C; Kovacs MJ; Solymoss S; Hinshaw K; Dwyer J; Smith G; McDonald S; Newstead-Angel J; McLeod A; Khandelwal M; Silver RM; Le Gal G; Greer IA; Keely E; Rosene-Montella K; Walker M; Wells PS;
Lancet; 2014 Nov; 384(9955):1673-83. PubMed ID: 25066248
[TBL] [Abstract][Full Text] [Related]
5. Venous thromboembolism, thrombophilia, antithrombotic therapy, and pregnancy: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition).
Bates SM; Greer IA; Pabinger I; Sofaer S; Hirsh J
Chest; 2008 Jun; 133(6 Suppl):844S-886S. PubMed ID: 18574280
[TBL] [Abstract][Full Text] [Related]
6. Compression stockings in addition to low-molecular-weight heparin to prevent venous thromboembolism in surgical inpatients requiring pharmacoprophylaxis: the GAPS non-inferiority RCT.
Shalhoub J; Lawton R; Hudson J; Baker C; Bradbury A; Dhillon K; Everington T; Gohel MS; Hamady Z; Hunt BJ; Stansby G; Warwick D; Norrie J; Davies AH
Health Technol Assess; 2020 Dec; 24(69):1-80. PubMed ID: 33275096
[TBL] [Abstract][Full Text] [Related]
7. [Thromboprophylaxis with low-molecular-weight heparin insufficient in high-risk pregnancy].
Roeters van Lennep JE; Meijer E; Klumper FJ; Middeldorp JM; Bloemenkamp KW; Middeldorp S
Ned Tijdschr Geneeskd; 2011; 155():A3433. PubMed ID: 21527059
[TBL] [Abstract][Full Text] [Related]
8. Effect of weight-adjusted intermediate-dose versus fixed-dose prophylactic anticoagulation with low-molecular-weight heparin on venous thromboembolism among noncritically and critically ill patients with COVID-19: the COVI-DOSE trial, a multicenter, randomised, open-label, phase 4 trial.
Zuily S; Lefèvre B; Sanchez O; Empis de Vendin O; de Ciancio G; Arlet JB; Khider L; Terriat B; Greigert H; Robert CS; Louis G; Trinh-Duc A; Rispal P; Accassat S; Thiery G; Montani D; Azarian R; Meneveau N; Soudet S; Le Mao R; Maurier F; Le Moing V; Quéré I; Yelnik CM; Lefebvre N; Martinot M; Delrue M; Benhamou Y; Parent F; Roy PM; Presles E; Goehringer F; Mismetti P; Bertoletti L; Rossignol P; Couturaud F; Wahl D; Thilly N; Laporte S;
EClinicalMedicine; 2023 Jun; 60():102031. PubMed ID: 37350990
[TBL] [Abstract][Full Text] [Related]
9. A Longitudinal Study of Thrombosis and Bleeding Outcomes With Thromboprophylaxis in Pregnant Women at Intermediate and High Risk of VTE.
Schapkaitz E; Libhaber E; Gerber A; Rhemtula H; Zamparini J; Jacobson BF; Büller HR
Clin Appl Thromb Hemost; 2023; 29():10760296231160748. PubMed ID: 36972476
[TBL] [Abstract][Full Text] [Related]
10. Edoxaban for venous thromboembolism in patients with cancer: results from a non-inferiority subgroup analysis of the Hokusai-VTE randomised, double-blind, double-dummy trial.
Raskob GE; van Es N; Segers A; Angchaisuksiri P; Oh D; Boda Z; Lyons RM; Meijer K; Gudz I; Weitz JI; Zhang G; Lanz H; Mercuri MF; Büller HR;
Lancet Haematol; 2016 Aug; 3(8):e379-87. PubMed ID: 27476789
[TBL] [Abstract][Full Text] [Related]
11. Aspirin or Low-Molecular-Weight Heparin for Thromboprophylaxis after a Fracture.
; O'Toole RV; Stein DM; O'Hara NN; Frey KP; Taylor TJ; Scharfstein DO; Carlini AR; Sudini K; Degani Y; Slobogean GP; Haut ER; Obremskey W; Firoozabadi R; Bosse MJ; Goldhaber SZ; Marvel D; Castillo RC
N Engl J Med; 2023 Jan; 388(3):203-213. PubMed ID: 36652352
[TBL] [Abstract][Full Text] [Related]
12. Prophylaxis of thromboembolism during therapy with asparaginase in adults with acute lymphoblastic leukaemia.
Rank CU; Lynggaard LS; Als-Nielsen B; Stock W; Toft N; Nielsen OJ; Frandsen TL; Tuckuviene R; Schmiegelow K
Cochrane Database Syst Rev; 2020 Oct; 10(10):CD013399. PubMed ID: 33038027
[TBL] [Abstract][Full Text] [Related]
13. Venous thromboembolism prophylaxis for women at risk during pregnancy and the early postnatal period.
Middleton P; Shepherd E; Gomersall JC
Cochrane Database Syst Rev; 2021 Mar; 3(3):CD001689. PubMed ID: 33779986
[TBL] [Abstract][Full Text] [Related]
14. Anticoagulants for thrombosis prophylaxis in acutely ill patients admitted to hospital: systematic review and network meta-analysis.
Eck RJ; Elling T; Sutton AJ; Wetterslev J; Gluud C; van der Horst ICC; Gans ROB; Meijer K; Keus F
BMJ; 2022 Jul; 378():e070022. PubMed ID: 35788047
[TBL] [Abstract][Full Text] [Related]
15. Early switch to oral anticoagulation in patients with acute intermediate-risk pulmonary embolism (PEITHO-2): a multinational, multicentre, single-arm, phase 4 trial.
Klok FA; Toenges G; Mavromanoli AC; Barco S; Ageno W; Bouvaist H; Brodmann M; Cuccia C; Couturaud F; Dellas C; Dimopoulos K; Duerschmied D; Empen K; Faggiano P; Ferrari E; Galiè N; Galvani M; Ghuysen A; Giannakoulas G; Huisman MV; Jiménez D; Kozak M; Lang IM; Lankeit M; Meneveau N; Münzel T; Palazzini M; Petris AO; Piovaccari G; Salvi A; Schellong S; Schmidt KH; Verschuren F; Schmidtmann I; Meyer G; Konstantinides SV;
Lancet Haematol; 2021 Sep; 8(9):e627-e636. PubMed ID: 34363769
[TBL] [Abstract][Full Text] [Related]
16. Tinzaparin vs Warfarin for Treatment of Acute Venous Thromboembolism in Patients With Active Cancer: A Randomized Clinical Trial.
Lee AYY; Kamphuisen PW; Meyer G; Bauersachs R; Janas MS; Jarner MF; Khorana AA;
JAMA; 2015 Aug; 314(7):677-686. PubMed ID: 26284719
[TBL] [Abstract][Full Text] [Related]
17. Prophylaxis for venous thromboembolic disease in pregnancy and the early postnatal period.
Bain E; Wilson A; Tooher R; Gates S; Davis LJ; Middleton P
Cochrane Database Syst Rev; 2014 Feb; (2):CD001689. PubMed ID: 24519568
[TBL] [Abstract][Full Text] [Related]
18. Recurrent venous thromboembolism in patients with pulmonary embolism and right ventricular dysfunction: a post-hoc analysis of the Hokusai-VTE study.
Brekelmans MP; Ageno W; Beenen LF; Brenner B; Buller HR; Chen CZ; Cohen AT; Grosso MA; Meyer G; Raskob G; Segers A; Vanassche T; Verhamme P; Wells PS; Zhang G; Weitz JI
Lancet Haematol; 2016 Sep; 3(9):e437-45. PubMed ID: 27570090
[TBL] [Abstract][Full Text] [Related]
19. Rivaroxaban compared with standard anticoagulants for the treatment of acute venous thromboembolism in children: a randomised, controlled, phase 3 trial.
Male C; Lensing AWA; Palumbo JS; Kumar R; Nurmeev I; Hege K; Bonnet D; Connor P; Hooimeijer HL; Torres M; Chan AKC; Kenet G; Holzhauer S; Santamaría A; Amedro P; Chalmers E; Simioni P; Bhat RV; Yee DL; Lvova O; Beyer-Westendorf J; Biss TT; Martinelli I; Saracco P; Peters M; Kállay K; Gauger CA; Massicotte MP; Young G; Pap AF; Majumder M; Smith WT; Heubach JF; Berkowitz SD; Thelen K; Kubitza D; Crowther M; Prins MH; Monagle P;
Lancet Haematol; 2020 Jan; 7(1):e18-e27. PubMed ID: 31699660
[TBL] [Abstract][Full Text] [Related]
20. Rivaroxaban versus no anticoagulation for post-discharge thromboprophylaxis after hospitalisation for COVID-19 (MICHELLE): an open-label, multicentre, randomised, controlled trial.
Ramacciotti E; Barile Agati L; Calderaro D; Aguiar VCR; Spyropoulos AC; de Oliveira CCC; Lins Dos Santos J; Volpiani GG; Sobreira ML; Joviliano EE; Bohatch Júnior MS; da Fonseca BAL; Ribeiro MS; Dusilek C; Itinose K; Sanches SMV; de Almeida Araujo Ramos K; de Moraes NF; Tierno PFGMM; de Oliveira ALML; Tachibana A; Chate RC; Santos MVB; de Menezes Cavalcante BB; Moreira RCR; Chang C; Tafur A; Fareed J; Lopes RD;
Lancet; 2022 Jan; 399(10319):50-59. PubMed ID: 34921756
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
